| The Aviara Breast Cancer IndexSM, a combination of
Aviara H/ISM (HOXB13:IL17BR) and Aviara MGISM (Molecular Grade Index), refines and improves risk
stratification in patients with estrogen receptor
(ER)-positive, lymph node-negative breast cancer.
Aviara H/I and Aviara MGI independently
evaluate distinct biological pathways.
- Aviara H/I is a two-gene index that stratifies
ER-positive breast cancer into low or high
risk for recurrence and is predictive of
benefit from endocrine therapy.1-4
- Aviara MGI is a five-gene index that provides
quantitative and objective molecular
assessment of tumor grade and proliferative
status, stratifies breast cancers into low or
high risk for recurrence5, and identifies tumors
likely to be responsive to chemotherapy.6,9
A simultaneous assessment of Aviara H/I and
Aviara MGI, expressed through the Aviara
Breast Cancer Index, provides independent and
complementary prognostic information useful
for treatment decisions.5 |
Risk Assessment in
Early Breast Cancer
Accurate assessment of prognosis in patients
with early stage breast cancer provides essential
information to guide adjuvant treatment
decisions. Traditionally, evaluation of prognosis
and risk of recurrence has been based on
clinicopathologic features.7 Patients identified
with Intermediate Risk features remain a
clinical challenge.
The Aviara Breast Cancer Index improves
patient management by refining risk
assessment and identifying patients likely to
benefit from endocrine therapy, and whose
tumors are likely to be sensitive or resistant
to chemotherapy. |
Aviara H/I and Aviara MGI Provide Independent and Significant
Prognostic Information5,8
References:
1 Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a
prognostic factor in early-stage breast cancer. J Clin Oncol., 24:4611-4619, 2006.
2 Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox
13 and interleukin-17B receptor for prediction of recurrence and survival in
women receiving adjuvant tamoxifen. Clin Cancer Res., 12: 2080-2087, 2006.
3 Jerevall PL, Brommesson S, Strand C, et al. Exploring the two-gene ratio in breast
cancer-independent roles for HOXB13 and IL17BR in prediction of clinical outcome
Breast Cancer Res Treat., 107:225-234, 2008.
4 Jansen MP, Sieuwerts AM, Look MP, et al. HOXB13-to-IL17BR expression ratio
is related with tumor aggressiveness and response to tamoxifen of recurrent
breast cancer: a retrospective study. J Clin Oncol., 25:66266-8, 2007.
5 Ma X-J, Salunga R, Dahiya S, et al: A five-gene molecular grade index and
HOXB13:IL17BR are complementary prognostic factors in early stage breast
cancer. Clin Cancer Res., 14(9):2601-2608, 2008.
6 Page DL, Gray R, Allred DC et al. Prediction of Node-Negative Breast Cancer
Outcome by Histologic Grading and S- Phase Analysis by Flow Cytometry: an
Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 2001; 24:10-8.
7 Goldhirsch A, Coates AS, Gelber RD, et al. First – select the target: better choice of
adjuvant treatment for breast cancer patients. Ann Oncol., 17:1772-1776, 2006.
8 AviaraDx, data on file.
9 Ma X-J, Erlander M, Goss P, et al. A robust five-gene RT-PCR molecular grade
index stratifies recurrence risk for grade 2 tumors, predicts chemo-sensitivity
and is compatible with formalin-fixed paraffin-embedded tissue. Program and
abstracts of the 25th Annual Miami Breast Cancer Conference; February 20-23, 2008, Orlando, Florida.
| TOP |
|
